Jeffrey L Evelhoch

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi Key factors in the acquisition of contrast kinetic data for oncology
    J L Evelhoch
    Cancer Biology Program, Barbara Ann Karmanos Cancer Institute, and Departments of Internal Medicine and Radiology, Wayne State University, Vaitkevicius MR Center, Detroit, Michigan 48201, USA
    J Magn Reson Imaging 10:254-9. 1999
  2. ncbi Applications of magnetic resonance in model systems: cancer therapeutics
    J L Evelhoch
    Barbara Ann Karmanos Cancer Institute and Department of Internal Medicine, Wayne State University, Detroit, MI, USA
    Neoplasia 2:152-65. 2000
  3. ncbi Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code HW04HO, Detroit, MI 48201, USA
    Invest New Drugs 26:159-67. 2008
  4. ncbi Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126
    Jeffrey L Evelhoch
    Karmanos Cancer Institute, Wayne State University, Harper Hospital MR Center, Detroit, Michigan 48201, USA
    Clin Cancer Res 10:3650-7. 2004

Detail Information

Publications4

  1. ncbi Key factors in the acquisition of contrast kinetic data for oncology
    J L Evelhoch
    Cancer Biology Program, Barbara Ann Karmanos Cancer Institute, and Departments of Internal Medicine and Radiology, Wayne State University, Vaitkevicius MR Center, Detroit, Michigan 48201, USA
    J Magn Reson Imaging 10:254-9. 1999
    ..This review considers these factors and, when possible, makes specific recommendations for addressing them experimentally...
  2. ncbi Applications of magnetic resonance in model systems: cancer therapeutics
    J L Evelhoch
    Barbara Ann Karmanos Cancer Institute and Department of Internal Medicine, Wayne State University, Detroit, MI, USA
    Neoplasia 2:152-65. 2000
    ....
  3. ncbi Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code HW04HO, Detroit, MI 48201, USA
    Invest New Drugs 26:159-67. 2008
    ..This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126...
  4. ncbi Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126
    Jeffrey L Evelhoch
    Karmanos Cancer Institute, Wayne State University, Harper Hospital MR Center, Detroit, Michigan 48201, USA
    Clin Cancer Res 10:3650-7. 2004
    ..CONCLUSIONS: The contrast enhanced-MRI measured median IAUC is a useful end point for quantifying ZD6126 antivascular effects in human tumors...